Ibex's Galen platform provides health systems and diagnostic laboratories with an integrated solution for cancer diagnosis and biomarker scoring. It is capable of detecting over 100 different cancer and non-cancer pathologies. The platform has been deployed in laboratories and pathology departments worldwide, including at the University of Pittsburgh Medical Center, and throughout Wales.
Key takeaways:
- Ibex Medical Analytics has closed a $55 million Series C financing round led by 83North, bringing its total funding to over $100 million since its inception in 2016.
- The company's Galen platform provides an integrated solution for cancer diagnosis and biomarker scoring, capable of detecting more than 100 different cancer and non-cancer pathologies.
- Ibex has achieved significant milestones recently, including live deployment of Galen at University of Pittsburgh Medical Center, national roll out throughout Wales, and collaboration with AstraZeneca and Daiichi Sankyo for breast cancer product development.
- The latest financing round will be used to expand Ibex's footprint in the United States, meet the increasing demand for AI-powered diagnostic solutions, and accelerate the growth of their product portfolio.